1. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
- Author
-
Olin RL, Vogl DT, Porter DL, Luger SM, Schuster SJ, Tsai DE, Siegel DL, Cook RJ, Mangan PA, Cunningham K, and Stadtmauer EA
- Subjects
- Adult, Aged, Disease Progression, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma mortality, Prognosis, Recurrence, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation mortality, Multiple Myeloma therapy, Salvage Therapy methods
- Abstract
Therapeutic options for patients with multiple myeloma whose disease has relapsed after a prior auto-SCT include novel biologic therapies, traditional chemotherapy or a second transplant, with no clear standard of care. Few published studies address the safety and efficacy of a second auto-SCT for relapsed disease. We reviewed the Abramson Cancer Center experience with salvage auto-SCT for relapsed multiple myeloma. Forty-one patients had received a salvage auto-SCT at our institution; the median time between transplants was 37 months (range 3-91). The overall response rate in assessable patients was 55%, and treatment-related mortality was 7%. With a median follow-up time of 15 months, the median PFS was 8.5 months and the median overall survival (OS) was 20.7 months. In a multivariate analysis of OS, independent prognostic factors were >or=5 prior lines of therapy and time to progression after initial auto-SCT of
- Published
- 2009
- Full Text
- View/download PDF